157 related articles for article (PubMed ID: 9151856)
21. An adenovirus type 5 (Ad5) amplicon-based packaging cell line for production of high-capacity helper-independent deltaE1-E2-E3-E4 Ad5 vectors.
Catalucci D; Sporeno E; Cirillo A; Ciliberto G; Nicosia A; Colloca S
J Virol; 2005 May; 79(10):6400-9. PubMed ID: 15858023
[TBL] [Abstract][Full Text] [Related]
22. Transgene amplification and persistence after delivery of retroviral vector and packaging functions with E1/E4-deleted adenoviruses.
Torrent C; Jullien C; Klatzmann D; Perricaudet M; Yeh P
Cancer Gene Ther; 2000 Aug; 7(8):1135-44. PubMed ID: 10975674
[TBL] [Abstract][Full Text] [Related]
23. Improved adenoviral vector for vascular gene therapy : beneficial effects on vascular function and inflammation.
Qian HS; Channon K; Neplioueva V; Wang Q; Finer M; Tsui L; George SE; McArthur J
Circ Res; 2001 May; 88(9):911-7. PubMed ID: 11349000
[TBL] [Abstract][Full Text] [Related]
24. Infection of endothelium with E1(-)E4(+), but not E1(-)E4(-), adenovirus gene transfer vectors enhances leukocyte adhesion and migration by modulation of ICAM-1, VCAM-1, CD34, and chemokine expression.
Rafii S; Dias S; Meeus S; Hattori K; Ramachandran R; Feuerback F; Worgall S; Hackett NR; Crystal RG
Circ Res; 2001 May; 88(9):903-10. PubMed ID: 11348999
[TBL] [Abstract][Full Text] [Related]
25. Trans-complementation of E1-deleted adenovirus: a new vector to reduce the possibility of codissemination of wild-type and recombinant adenoviruses.
Imler JL; Bout A; Dreyer D; Dieterlé A; Schultz H; Valerio D; Mehtali M; Pavirani A
Hum Gene Ther; 1995 Jun; 6(6):711-21. PubMed ID: 7548271
[TBL] [Abstract][Full Text] [Related]
26. Downregulation of CXCR4 gene expression in primary human endothelial cells following infection with E1(-)E4(+) adenovirus gene transfer vectors.
Ramalingam R; Worgall S; Rafii S; Crystal RG
Mol Ther; 2000 Oct; 2(4):381-6. PubMed ID: 11020354
[TBL] [Abstract][Full Text] [Related]
27. Prolonged transgene expression in cotton rat lung with recombinant adenoviruses defective in E2a.
Engelhardt JF; Litzky L; Wilson JM
Hum Gene Ther; 1994 Oct; 5(10):1217-29. PubMed ID: 7849095
[TBL] [Abstract][Full Text] [Related]
28. Development of a complementing cell line and a system for construction of adenovirus vectors with E1 and E2a deleted.
Zhou H; O'Neal W; Morral N; Beaudet AL
J Virol; 1996 Oct; 70(10):7030-8. PubMed ID: 8794347
[TBL] [Abstract][Full Text] [Related]
29. Diminishing adenovirus gene expression and viral replication by promoter replacement.
Fang B; Koch P; Roth JA
J Virol; 1997 Jun; 71(6):4798-803. PubMed ID: 9151874
[TBL] [Abstract][Full Text] [Related]
30. Efficient gene delivery to the inflamed colon by local administration of recombinant adenoviruses with normal or modified fibre structure.
Wirtz S; Galle PR; Neurath MF
Gut; 1999 Jun; 44(6):800-7. PubMed ID: 10323880
[TBL] [Abstract][Full Text] [Related]
31. Combination therapy with conditionally replicating adenovirus and replication defective adenovirus.
Lee CT; Park KH; Yanagisawa K; Adachi Y; Ohm JE; Nadaf S; Dikov MM; Curiel DT; Carbone DP
Cancer Res; 2004 Sep; 64(18):6660-5. PubMed ID: 15374981
[TBL] [Abstract][Full Text] [Related]
32. Effects of first generation E1E3-deleted and second generation E1E3E4-deleted/modified adenovirus vectors on human endothelial cell death.
Jornot L; Petersen H; Lusky M; Pavirani A; Moix I; Morris ; Rochat T
Endothelium; 2001; 8(3):167-79. PubMed ID: 11824470
[TBL] [Abstract][Full Text] [Related]
33. Differential influence of the E4 adenoviral genes on viral and cellular promoters.
Grave L; Dreyer D; Dieterle A; Leroy P; Michou AI; Doderer C; Pavirani A; Lusky M; Mehtali M
J Gene Med; 2000; 2(6):433-43. PubMed ID: 11199264
[TBL] [Abstract][Full Text] [Related]
34. Regulation of adenovirus-mediated transgene expression by the viral E4 gene products: requirement for E4 ORF3.
Lusky M; Grave L; Dieterlé A; Dreyer D; Christ M; Ziller C; Furstenberger P; Kintz J; Hadji DA; Pavirani A; Mehtali M
J Virol; 1999 Oct; 73(10):8308-19. PubMed ID: 10482581
[TBL] [Abstract][Full Text] [Related]
35. A packaging cell line for propagation of recombinant adenovirus vectors containing two lethal gene-region deletions.
Wang Q; Jia XC; Finer MH
Gene Ther; 1995 Dec; 2(10):775-83. PubMed ID: 8750018
[TBL] [Abstract][Full Text] [Related]
36. Effects of the deletion of early region 4 (E4) open reading frame 1 (orf1), orf1-2, orf1-3 and orf1-4 on virus-host cell interaction, transgene expression, and immunogenicity of replicating adenovirus HIV vaccine vectors.
Thomas MA; Song R; Demberg T; Vargas-Inchaustegui DA; Venzon D; Robert-Guroff M
PLoS One; 2013; 8(10):e76344. PubMed ID: 24143187
[TBL] [Abstract][Full Text] [Related]
37. Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo.
Lieber A; He CY; Kirillova I; Kay MA
J Virol; 1996 Dec; 70(12):8944-60. PubMed ID: 8971024
[TBL] [Abstract][Full Text] [Related]
38. Lack of persistence of E1- recombinant adenoviral vectors containing a temperature-sensitive E2A mutation in immunocompetent mice and hemophilia B dogs.
Fang B; Wang H; Gordon G; Bellinger DA; Read MS; Brinkhous KM; Woo SL; Eisensmith RC
Gene Ther; 1996 Mar; 3(3):217-22. PubMed ID: 8646552
[TBL] [Abstract][Full Text] [Related]
39. Transfer of the CFTR gene to the lung of nonhuman primates with E1-deleted, E2a-defective recombinant adenoviruses: a preclinical toxicology study.
Goldman MJ; Litzky LA; Engelhardt JF; Wilson JM
Hum Gene Ther; 1995 Jul; 6(7):839-51. PubMed ID: 7578403
[TBL] [Abstract][Full Text] [Related]
40. Decreased replication ability of E1-deleted adenoviruses correlates with increased brain tumor malignancy.
Ghosh S; Duigou GJ
Cancer Res; 2005 Oct; 65(19):8936-43. PubMed ID: 16204066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
